Key Takeaways
- Revenue surged 47% YoY to ₹400 crores, powered by the B2C segment scaling from 4% to 13% of revenue and the US subsidiary growing ~40% in H1.
- Consolidated margins tell a two-speed story: B2B and B2C segments each deliver 32–35%+ EBITDA margins, but the high-volume, low-margin US RLD distribution business (80% of revenue) pulls consolidated EBITDA down to 6.75%.
- The margin improvement thesis rests on mix shift: management is targeting B2C to reach 25% of revenue within 1.5 years, which would lift PAT margins from 5% toward 8–10%.
- Africa strategy is deliberately narrow: the company avoids tenders entirely there, focusing instead on private-market niche molecules where competition is thin and gross margins are higher.
- What to watch next quarter: whether B2C revenue share continues its trajectory toward the 18–20% FY26 target, the pace of new country entries (Kenya, Chile, Algeria), and any quantification of the clinical trials subsidiary's margin contribution in H2.
The Two-Speed Margin Structure
- B2B and B2C are high-margin engines: standalone B2B delivers 32–33% EBITDA margins and B2C delivers 35%+, yet consolidated EBITDA sits at just ~7% because the US subsidiary (Espee) contributes ~80% of revenue on a thin-margin RLD distribution model.
- US subsidiary is profitable, not a drag: Espee operates a high-volume, high-ROE business supplying reference listed drugs to big pharma for research and development, requires no capital infusion, and has already returned 80–90% of the acquisition cost through profits.
- The margin bridge is B2C mix: PAT margin improvement from 5% to 8–10% is driven entirely by growing the higher-margin B2C segment, which management targets at 25% of revenue within 1.5 years, up from 13% today.
- B2C margins have further room: management expects to improve B2C EBITDA margins beyond the current 35%+ as they penetrate deeper into existing markets.
Anjali Shah: "we are looking at a better percentage in future with at least moving ahead to what is 5% now. I think we can move ahead to 8-10% is something that we are eyeing. But eventually we will see how the operations add up and at what period they add up."
B2C: The Growth and Margin Pivot
- B2C scaled from 4% to 13% of revenue and is targeted to reach 18–20% before the end of this financial year, with a medium-term goal of 25% within 1.5 years.
- Institutional government supplies have been carved out as a third business category alongside B2B and B2C, routable through subsidiaries as B2C or through distributors as B2B depending on the market.
- Nicaragua tender win secured two key product awards, and the company is actively participating in national tenders across multiple countries with submissions of over 20 products per market.
- Bolivia subsidiary (Relius Pharma SRL) delivered strong performance with commercial launches across cardiovascular, hematology, neurology, and anti-infectives.
- Rivastigmine patches were launched across multiple Latin American markets, marking entry into a new therapeutic segment; a pipeline of dermal patches for other categories is in development.
Geographic Expansion: Emerging Markets Plus the US Base
- Latin America is the strongest footprint, with pharmaceutical formulations reaching patients in more than 40 countries overall.
- New market entries are deliberate and gated: management personally visits every country before committing, and the approach is to test markets before establishing full-fledged subsidiaries.
- Algeria entry has begun with product registration activities and a tech-transfer and licensing deal that will generate royalties on locally manufactured products.
- Kenya, Chile, and Dominican Republic are on the near-term radar; 40 products are being registered in Kenya and 37 new approvals were secured in the ASEAN region.
- Emerging markets are expected to grow from ~20% of total revenue to 25–30%, while the US subsidiary continues growing at a stable pace; both businesses are expected to maintain growth consistent with recent H1 and quarterly trends.
Arpit Shah: "unless and until I personally or someone from my team personally don't visit the country, we don't start working on that."
Africa: A Deliberately Narrow, High-Margin Play
- Africa business is small and private-market only: the company does not participate in African tenders due to cutthroat competition on cost and pricing, focusing instead on niche and rare molecules where competition is limited.
- The portfolio is ~35 products sold at lower volumes but higher gross margins; the strategy targets the 20% of the market that generates better PAT levels rather than competing for the 80% tender-driven volume.
- Management did not address how it would handle African tender rules giving first priority to local manufacturers, or the analyst's observation that African manufacturers hold a 25% cost advantage, redirecting instead to the private-market niche strategy.
Arpit Shah: "you said why we are not picking 80% of the market. I think my shareholders will be happy that I am picking something which is 20% but getting better PAT levels on that."
Product Portfolio and Capabilities
- Over 95% of exports come from advanced and niche formulations: tablets, injections, inhalers, soft gels, and oral suspensions.
- Rivastigmine patches represent the first move into a new therapeutic segment via transdermal delivery, with additional dermal patch products in the pipeline for other therapeutic categories.
- 37 new approvals were secured in the ASEAN region during the quarter.
- A new subsidiary for clinical trials research services is being set up and is expected to become operational and margin-accretive in H2.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| B2C revenue share | Reach 18–20% of total revenue (from 13% currently) | Before end of FY26 |
| B2C revenue share | Reach 25% of total revenue | Next 1.5 years |
| PAT margin | Improve from 5% to 8–10% | 1–2 years, depending on operational factors |
| Clinical trials subsidiary | Operational and adding to margins | H2 FY26 |
| Emerging market revenue share | Grow from ~20% to 25–30% of total revenue | No fixed date; both US and emerging businesses to grow at recent pace |
| New country entries | Kenya (40 products registering), Chile, Dominican Republic, Algeria | Underway; gated by management due diligence visits |
Key Metrics
| Metric | Q2 FY26 |
|---|---|
| Revenue | ₹400 cr, +47% YoY |
| Operational EBITDA | ₹27 cr, +28% YoY |
| EBITDA margin | 6.75% |
| PAT after minority interest | ₹17.5 cr, +34% YoY |
| PAT margin | 5%, management targeting 8–10% going forward |
| B2C revenue share | 13% of total revenue, up from 4% in prior-year H1 |
| B2B revenue share | 87% of total revenue |
| B2C revenue share target | 18–20% by end of FY26, 25% in next 1.5 years |
| B2B segment EBITDA margin | 32–33% (Remus standalone and Bolivian/Guatemalan subsidiary) |
| B2C segment EBITDA margin | 35%+ |
| US subsidiary revenue share | ~80% of consolidated revenue |
| US subsidiary standalone revenue growth | ~40% (H1 FY26 vs H1 FY25) |
| New product approvals secured | 37 during the period |
| National tender submissions | Over 20 products per market |
| Countries with product reach | More than 40 |